The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Tivozanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TIVO
- 07 Jun 2017 Biomarkers information updated
- 19 Feb 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 19 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.